Gain detailed insights into the trading activity of Congress members for Relay Therapeutics on our government trades page. Stay updated on how elected officials are investing in RLAY.

Relay Therapeutics - Government Trades

Relay Therapeutics

Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).

News

RLAY

Relay Therapeutics shares are trading lower by 17.8% during Wednesday&#39;s session. The company priced its $200 million offering.

Why Relay Therapeutics (RLAY) Stock Is Down 17% Today

analyst ratings image

Downgrades

Markets

Analyst Ratings

Trading Ideas

ACET

ANIP

SUPN

This Novartis Analyst Is No Longer Bullish; Here Are Top Downgrades For Wednesday

GameStopPre-market: 5 titoli da monitorare oggi, 10 settembre 2024

Pre-Market Outlook

Movers

EVGO

WOOF

GameStop Reports Weak Sales, Joins Petco, Relay Therapeutics And Other Big Stocks Moving Lower In Wednesday&#39;s Pre-Market Session

movers image

AILE

ALTM

BKYI

CNEY

FTCI

MPLN

PLAY

SLXN

SXTC

TANH

TBIO

TOMZ

Why Dave &amp; Buster&#39;s Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket

Analyst Color

Biotech

Health Care

Price Target

General

Relay Therapeutics shares interim data for RLY-2608 from the ReDiscover study, showing a 57% clinical benefit rate. Oppenheimer downgrades Relay Therapeutics from Outperform to Perform, citing concerns about competitor data and efficacy challenges.

Relay Therapeutics Faces Downgrade Over Efficacy Concerns in Competitive PI3K Inhibitor Market

Stock market analysts

Upgrades

ORCL

This Johnson Controls International Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday

Market,Sentiment,,Fear,And,Greed,Index,,Emotional,On,Stock,Market

Earnings

NVDA

Dow Jumps Over 1% Following Last Week&#39;s Selloff: Investor Sentiment Improves, But Fear &amp; Greed Index Remains In &#39;Fear&#39; Zone

Crude-oil-4-logo

Equities

Eurozone

Commodities

Intraday Update

AMCX

CSWI

EGIO

Intelligent Bio Solutions Inc. - Common Stock

INBS

PEGY

SINT

Crude Oil Gains Over 1%; Relay Therapeutics Shares Spike Higher

Wall Street, US stocks

Nasdaq Surges Over 1%; US Wholesale Inventories Rise 0.2% In July

Cancer-Image by PDPics from Pixabay-

Monday, Relay Therapeutics Inc. (NASDAQ:RLAY) shared interim data for RLY-2608 from ReDiscover study, an ongoing first-in-human study, to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary antitumor activity of RLY-2608 alone, in combination with fulvestrant, and combinati

Relay Therapeutics Advances Towards Pivotal Trial As It Shares Encouraging Breast Cancer Data In Heavily Pretreated Patients

Relay Therapeutics Inc

Press Releases

Relay Therapeutics Reports Third Quarter 2024 Financial Results and Corporate Highlights

Relay Therapeutics to Participate in Upcoming Investor Conferences

Relay Therapeutics and Elevar Therapeutics Announce Exclusive Global Licensing Agreement for Lirafugratinib in FGFR2-Driven Cholangiocarcinoma and Other Solid Tumors

Elevar Therapeutics and Relay Therapeutics Announce Exclusive Global Licensing Agreement for Lirafugratinib in FGFR2-Driven Cholangiocarcinoma and Other Solid Tumors

Relay Therapeutics to Present Updated Clinical Data on RLY-2608 in HR+/HER2- Breast Cancer at 2024 San Antonio Breast Cancer Symposium

Relay Therapeutics Announces Updated Interim Data for RLY-2608 + Fulvestrant Demonstrating Continued Maturation of Clinically Meaningful Progression Free Survival

Relay Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference

Relay Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights on February 26, 2025

Relay Therapeutics to Participate in Two Upcoming Investor Conferences

Relay Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates

Government Trades

Relay Therapeutics Inc

top performing RLAY trades

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga